Consumption of Bovine Spongiform Encephalopathy (BSE) Contaminated Beef and the Risk of Variant Creutzfeldt-Jakob Disease

Risk Analysis

Volumn 33, Issue 11, 2013, Pages 1958-1968

  Chen, Chu Chih ^a   Wang, Yin Han ^a   Wu, Kuen Yuh ^b  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Clinical threshold; Cross species barrier; Exposure threshold; Incubation period; Poisson process

Indexed keywords

CLINICAL THRESHOLD; CROSS-SPECIES; EXPOSURE THRESHOLD; INCUBATION PERIODS; POISSON PROCESS;

MAMMALS; NEURODEGENERATIVE DISEASES; RISK ASSESSMENT; STOCHASTIC MODELS;

RISK PERCEPTION;

BOVINE SPONGIFORM ENCEPHALOPATHY; BRAIN; CREUTZFELDT JAKOB DISEASE; DATA ACQUISITION; EPIDEMIC; HEALTH RISK; INCUBATION; INFECTIVITY; MEAT; PROBABILITY;

UNITED KINGDOM;

BOVINAE; BOVINE SPONGIFORM ENCEPHALOPATHY PRION; MACACA;

ANIMAL; ARTICLE; BOVINE SPONGIFORM ENCEPHALOPATHY; CATTLE; CLINICAL THRESHOLD; CREUTZFELDT JAKOB DISEASE; CROSS-SPECIES BARRIER; DISEASE TRANSMISSION; EXPOSURE THRESHOLD; HUMAN; INCIDENCE; INCUBATION TIME; MEAT; POISSON PROCESS; RISK FACTOR; THEORETICAL MODEL; UNITED KINGDOM; VIROLOGY;

CLINICAL THRESHOLD; CROSS-SPECIES BARRIER; EXPOSURE THRESHOLD; INCUBATION PERIOD; POISSON PROCESS;

ANIMALS; CATTLE; CREUTZFELDT-JAKOB SYNDROME; ENCEPHALOPATHY, BOVINE SPONGIFORM; GREAT BRITAIN; HUMANS; INCIDENCE; MEAT PRODUCTS; MODELS, THEORETICAL; RISK FACTORS;

EID: 84887401934     PISSN: 02724332     EISSN: 15396924     Source Type: Journal    
DOI: 10.1111/risa.12079     Document Type: Article

References (48)

1. Collinge J. Molecular neurology of prion disease. Journal of Neurology, Neurosurgery, and Psychiatry, 2005; 76:906-919.
2. Tan L, Williams MA, Khan MK, Champion HC, Nielsen NH. Risk of transmission of bovine spongiform encephalopathy to humans in the United States. Journal of the American Medical Association, 1999; 281(24):2330-2339.
3. Valleron AJ, Boelle PY, Will R, Cesbron JY. Estimation of epidemic size and incubation time based on age characteristics of vCJD in the United Kingdom. Science, 2001; 294:1726-1728.
4. Belay ED, Schonberger LB. The public health impact of prion diseases. Annual Review of Public Health, 2005; 26:191-212.
5. UK Creutzfeldt-Jakob Disease Surveillance Unit. Available at: http://www.cjd.ed.ac.uk/ Accessed January 31, 2013.
6. Anderson RM, Donnelly CA, Ferguson NM, Woolhouse MEJ, Watt CJ, Udy HJ, MaWhinney S, Dunstan SP, Southwood TRE, Wilesmith JW, Ryan JBM, Hoinville LJ, Hillerton JE, Austin AR, Wells GAH. Transmission dynamics and epidemiology of BSE in British cattle. Nature, 1996; 382:779-788.
7. Huillard d'Aignaux JN, Cousens SN, Smith, PG. Predictability of the UK variant Creutzfeldt-Jakob disease epidemic. Science, 2001; 294:1729-1731.
8. Huillard d'Aignaux JN, Cousens SN, Smith, PG. The predictability of the epidemic of variant Creutzfeldt-Jakob disease by back-calculation methods. Statistical Methods in Medical Research, 2003; 12:203-220.
9. Ghani AC, Ferguson NM, Donnelly CA, Anderson RM. Predicted vCJD mortality in Great Britain. Nature, 2000; 406:583-584.
10. Ghani AC, Donnelly CA, Ferguson NM, Anderson RM. The transmission dynamics of BSE and vCJD. Comptes Rendus Biologies, 2002; 325:37-47.
11. Ghani AC, Ferguson NM, Donnelly CA, Anderson RM. Short-term projections for variant Creutzfeldt-Jakob disease onsets. Statistical Methods in Medical Research, 2003; 12:191-201.
12. Ghani AC, Ferguson NM, Donnelly CA, Hagenaars TJ, Anderson RM. Estimation of the number of people incubating variant CJD. Lancet, 1998; 352:1353-1354.
13. Cousens SN, Vynnycky E, Zeidler M, Will RG, Smith PG. Predicting the CJD epidemic in humans. Nature, 1997; 385:197-198.
14. Crist EPM. Transmissible spongiform encephalopathy risk assessment: The UK experience. Risk Analysis, 2005; 25(3):519-532.
15. Cummins JD, Grace PM, McDonnell KP, Ward SM. Predictive modelling and risk assessment of BSE: A review. Journal of Risk Research, 2001; 4:251-274.
16. de Koeijer AA, Havelaar A. The future of BSE risk assessments. Risk Analysis, 2007; 27(5):1091-1093.
17. de Koeijer AA. Analyzing BSE transmission to quantify regional risk. Risk Analysis, 2007; 27(5):1095-1103.
18. Hogasen HR, de Koeijer AA. Quantitative risk assessment for bovine spongiform encephalopathy in low- or zero-prevalence countries: The example of Norway. Risk Analysis, 2007; 27(5):1105-1117.
19. Calavas D, Supervie V, Morignat E, Costagliola D, Ducrot C. Complementary approach of data analysis and modeling to estimate the pattern of the BSE epidemic: The example of France. Risk Analysis, 2007; 27(5):1141-1150.
20. Gale P. Quantitative BSE risk assessment: Relating exposures to risk. Letters in Applied Microbiology, 1998; 27:239-242.
21. Gale P. BSE risk assessments in the UK: A risk tradeoff? Journal of Applied Microbiology, 2006; 100:417-427.
22. DNV. Assessment of the Risk from Possible BSE Infectivity in Dorsal Root Ganglia. Report for the UK Ministry of Agriculture, Fisheries and Food and the Spongiform Encephalopathy Advisory Committee. Det Norske Veritas, Report No. C7831, London, 1997.
23. McLean AR, Bostock CJ. Scrapie infections initiated at varying doses: An analysis of 117 titration experiments. Philosophical Transactions of the Royal Society of London, Series B, 2000; 355:1043-1050.
24. Baier M, Norley S, Schultz J, Burwinkel M, Schwarz A, Riemer C. Prion disease: Infectious and lethal doses following oral challenge. Journal of General Virology, 2003; 84:1927-1929.
25. Gravenor MB, Stallard N, Curnow R, McLean AR. Repeated challenge with prion disease: The risk of infection and impact on incubation period. Proceedings of the National Academy of Sciences of the United States of America, 2003; 100(19):10960-10965.
26. Kulkarni RV, Slepoy A, Singh RRP, Cox DL, Pázmándi F. Theoretical modeling of prion disease incubation. Biophysical Journal, 2003; 85:707-718.
27. De Koeijer A, Schreuder B, Bouma A. Factors that influence the age distribution of BSE cases: Potentials for age targeting in surveillance. Livestock Production Science, 2002; 76:223-233.
28. Saegerman C, Speybroeck N, Vanopdenbosch E, Wilesmith JW, Berkvens D. Trends in age at detection in cases of bovine spongiform encephalopathy in Belgium: An indicator of the epidemic curve. Veterinary Record, 2006; 159:583-587.
29. Ferguson NM, Donnelly CA, Woolhouse EJ, Anderson RM. The epidemiology of BSE in cattle herds in Great Britain. II. Model construction and analysis of transmission dynamics. Philosophical Transactions of the Royal Society of London, Series B, 1997; 352:803-838.
30. Lasmézas CI, Deslys JP, Demalmay R, Adjou KT, Lamoury F, Dormont D, Robain O, Ironside J, Hauw JJ. BSE transmission to macaques. Nature, 1996; 381:743-744.
31. Lasmézas CI, Fournier JG, Nouvel V, Boe H, Marcé D, Lamoury F, Kpp N, Hauw JJ, Ironside J, Bruce M, Dormont D, Deslys JP. Adaptation of the bovine spongiform encephalopathy agent to primates and comparison with Crutzfeldt-Jacob disease: Implications for human health. Proceedings of the National Academy of Sciences of the United States of America, 2001; 98:4142-4147.
32. Herzog C, Salès N, Charbonnier A, Freire S, Dormont D, Deslys JP, Lasmézas CI. Tissue distribution of bovine spongiform encephalopathy agent in primates after intravenous or oral infection. Lancet, 2004; 363:422-428.
33. Lasmézas CI, Comoy E, Hawkins S, Herzog C, Mouthon F, Konold T, Auvré F, Correia E, Lescoutra-Etchegaray N, Salés N, Wells G, Deslys JP. Risk of oral infection with bovine spongiform encephalopathy agent in primates. Lancet, 2005; 365:781-783.
34. SAS Version 9.2. Cary, NC: SAS Institute.
35. Commer PJ, Huntly PJ. Exposure of the human population to BSE infectivity over the course of the BSE epidemic in Great Britain and the impact of changes to the over thirty month rule. Journal of Risk Research, 2004; 7:523-543.
36. Science Steering Committee. Opinion and Report: Assessment of the human BSE risk posed by bovine vertebral column including dorsal root granglia, Adopted by the SSC at its meeting of May 16, 2002.
37. Ferguson NM, Donnelly CA. Assessment of the risk posed by bovine spongiform encephalopathy in cattle in Great Britain and the impact of potential changes to current control measures. Proceedings of the Royal Society of London, Series B, 2003; 270:1579-1584.
38. Arnold ME, Hawkins SAC, Green R, Dexter I, Wells GAH. Pathogenesis of experimental bovine spongiform encephalopathy (BSE): Estimation of tissue infectivity according to incubation period. Veterinary Research, 2009; 40:1-12.
39. Spongiform Encephalopathy Advisory Committee (SEAC). Likely impact on the risk to human health of reducing the level of BSE testing of healthy cattle slaughtered for food, 2011.
40. DNV. Sources of BSE Infectivity for UK Food Standards Agency. Det Norske Veritas Report 20016400, Ver. 3, October 2002.
41. The National Diet and Nutrition Survey (NDNS), U.K. Available at: www.food.gov.uk/multimedia/pdfs/publication/ndnstables0809.pdf, Accessed June 15, 2011.
42. Cooper JD, Bird SM. UK dietary exposure to BSE in beef mechanically recovered meat: By birth-cohort and gender. Journal of Cancer Epidemiology and Prevention, 2002; 7:59-70.
43. Office of National Statistics U.K. Available at: http://www.statistics.gov.uk/StatBase, Accessed May 21, 2011.
44. Chen CC, Wang YH, Wu, KY, Chang HY. Prevalence of variant Creutzfeldt-Jakob disease in the UK: Estimation from dietary exposure to bovine spongiform encephalopathy during the period 1980 to 1996. Unpublished manuscript.
45. Andrews NJ. Incidence of variant Creutzfeldt-Jakob disease diagnoses and deaths in the UK. Statistics Unit, Centre for Infections, Health Protection Agency, July 2, 2012.
46. Van Keulen LJM, van Zijderveld FV. TSE pathogenesis in cattle and sheep. Veterinary Research, 2008; 39(24):1-12.
47. Béringue V, Vilotte J-L, Laude H. Prion agent diversity and species barrier. Veterinary Research, 2008; 39(47):1-30.
48. Ross SM. Stochastic Processes. New York: John Wiley & Sons, Inc, 1983.